Sandra Dangelo is an Oncologist in New York, New York. Dangelo has been practicing medicine for over 19 years and is rated as an Elite expert by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. She is also highly rated in 35 other conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, Synovial Sarcoma, and Liver Embolization. Dangelo is currently accepting new patients.
Sonali Smith is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Smith has been practicing medicine for over 29 years and is rated as an Elite expert by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. She is also highly rated in 34 other conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Smith is currently accepting new patients.
Anas Younes is an Oncologist in New York, New York. Younes has been practicing medicine for over 40 years and is rated as an Elite expert by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. He is also highly rated in 26 other conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Classical Hodgkin Lymphoma, and Hodgkin Lymphoma.
Summary: This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirement...
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses.